To include your compound in the COVID-19 Resource Center, submit it here.

Owkin: machine learning with privacy protection

Owkin deploys AI solutions using real-world data to optimize drug development while maintaining patient privacy

To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions.

Gilles Wainrib, Owkin’s co-founder and CSO, said that although drug development is often based on the analysis of small data sets from clinical trials, hospitals generate a large amount of real-world data that can be used to optimize drug development.

Hospitals, especially those in the U.S., do not want to share

Read the full 805 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE